How to manage Pseudomonas aeruginosa infections

Matteo Bassetti(Ospedale Policlinico San Martino), Benoît Guéry(Université de Lille)

Drugs in Context

May 29, 2018

10.7573/dic.212527

Cited by 743

Related Papers

Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium

|Clinical Infectious Diseases|2019|2.8k

DALI: Defining Antibiotic Levels in Intensive Care Unit Patients: Are Current -Lactam Antibiotic Doses Sufficient for Critically Ill Patients?

|Clinical Infectious Diseases|2014|1.1k

Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper#

|Intensive Care Medicine|2020|1.1k

European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine)

|Clinical Microbiology and Infection|2021|1k

Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With <i>E coli</i> or <i>Klebsiella pneumoniae</i> Bloodstream Infection and Ceftriaxone Resistance

|JAMA|2018|761